Tomas Leanderson

Lund University — Sweden

Immunology and Microbiology · Life Sciences

44h-index6.2kcitations185works0.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

T-cell and B-cell Immunology(57), Immune Cell Function and Interaction(50), Immunotherapy and Immune Responses(33), Monoclonal and Polyclonal Antibodies Research(32), Immune Response and Inflammation(31)

Publications184 total

Supplementary Figure Legends from Tasquinimod Modulates Suppressive Myeloid Cells and Enhances Cancer Immunotherapies in Murine Models
2023Open Access
Supplementary Figure Legends from Tasquinimod Modulates Suppressive Myeloid Cells and Enhances Cancer Immunotherapies in Murine Models
2023Open Access
Supplementary Figure 2 from Tasquinimod Modulates Suppressive Myeloid Cells and Enhances Cancer Immunotherapies in Murine Models
2023Open Access
Supplementary Figure 5 from Tasquinimod Modulates Suppressive Myeloid Cells and Enhances Cancer Immunotherapies in Murine Models
2023Open Access
Supplementary Figure 3 from Tasquinimod Modulates Suppressive Myeloid Cells and Enhances Cancer Immunotherapies in Murine Models
2023Open Access
Data from Tasquinimod Modulates Suppressive Myeloid Cells and Enhances Cancer Immunotherapies in Murine Models
2023Open Access
Data from Tasquinimod Modulates Suppressive Myeloid Cells and Enhances Cancer Immunotherapies in Murine Models
2023Open Access
Supplementary Figure 1 from Tasquinimod Modulates Suppressive Myeloid Cells and Enhances Cancer Immunotherapies in Murine Models
2023Open Access
Supplementary Figure 4 from Tasquinimod Modulates Suppressive Myeloid Cells and Enhances Cancer Immunotherapies in Murine Models
2023Open Access
Supplementary Figure 5 from Tasquinimod Modulates Suppressive Myeloid Cells and Enhances Cancer Immunotherapies in Murine Models
2023Open Access
Supplementary Figure 3 from Tasquinimod Modulates Suppressive Myeloid Cells and Enhances Cancer Immunotherapies in Murine Models
2023Open Access
Supplementary Figure 4 from Tasquinimod Modulates Suppressive Myeloid Cells and Enhances Cancer Immunotherapies in Murine Models
2023Open Access
Supplementary Figure 2 from Tasquinimod Modulates Suppressive Myeloid Cells and Enhances Cancer Immunotherapies in Murine Models
2023Open Access
Supplementary Figure 6 from Tasquinimod Modulates Suppressive Myeloid Cells and Enhances Cancer Immunotherapies in Murine Models
2023Open Access
Supplementary Figure 1 from Tasquinimod Modulates Suppressive Myeloid Cells and Enhances Cancer Immunotherapies in Murine Models
2023Open Access
Supplementary Figure 6 from Tasquinimod Modulates Suppressive Myeloid Cells and Enhances Cancer Immunotherapies in Murine Models
2023Open Access
Data from Tasquinimod Is an Allosteric Modulator of HDAC4 Survival Signaling within the Compromised Cancer Microenvironment
2023Open Access
Supplementary File 1 from Tasquinimod Is an Allosteric Modulator of HDAC4 Survival Signaling within the Compromised Cancer Microenvironment
2023Open Access
Supplementary File 1 from Tasquinimod Is an Allosteric Modulator of HDAC4 Survival Signaling within the Compromised Cancer Microenvironment
2023Open Access
Supplementary Figures 1-4 from Tasquinimod Is an Allosteric Modulator of HDAC4 Survival Signaling within the Compromised Cancer Microenvironment
2023Open Access
page 1 of 10Next →

Frequent Co-authors

Fredrik Ivars(11), Anders Olsson(9), Eva Källberg(9), Per Björk(6), Thomas Vogl(6), David Liberg(6), Johannes Roth(6), Christian Lood(5), Anders Bengtsson(4), Mikael Sigvardsson(4), Helena Tydén(4), Marie Törngren(4), Anders Björk(3), Martin Stenström(3), Lena Erlandsson(3), Ronald W. Pero(3), Nils Lycke(3), Matteo Riva(3), Bengt Axelsson(3), Anette Sundstedt(3)